Insider Selling: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CEO Sells $244,752.64 in Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CEO Thomas A. Mccourt sold 139,064 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $244,752.64. Following the completion of the sale, the chief executive officer now directly owns 1,160,634 shares in the company, valued at approximately $2,042,715.84. This trade represents a 10.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ IRWD opened at $1.92 on Friday. Ironwood Pharmaceuticals, Inc. has a 1 year low of $1.59 and a 1 year high of $15.65. The stock has a market cap of $307.25 million, a P/E ratio of -64.00 and a beta of 0.29. The firm has a 50-day moving average of $3.57 and a 200 day moving average of $4.15.

Analyst Ratings Changes

IRWD has been the subject of several research analyst reports. Craig Hallum dropped their target price on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, January 22nd. JMP Securities dropped their target price on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a research report on Thursday, January 30th. Finally, StockNews.com cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Ironwood Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $10.67.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of IRWD. KBC Group NV raised its holdings in Ironwood Pharmaceuticals by 59.3% in the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock worth $35,000 after buying an additional 3,198 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Ironwood Pharmaceuticals by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,932 shares of the biotechnology company’s stock worth $150,000 after buying an additional 3,209 shares during the last quarter. Creative Planning raised its holdings in Ironwood Pharmaceuticals by 12.7% in the third quarter. Creative Planning now owns 42,151 shares of the biotechnology company’s stock worth $174,000 after buying an additional 4,749 shares during the last quarter. Quantinno Capital Management LP raised its holdings in Ironwood Pharmaceuticals by 40.0% in the third quarter. Quantinno Capital Management LP now owns 19,191 shares of the biotechnology company’s stock worth $79,000 after buying an additional 5,482 shares during the last quarter. Finally, Swiss National Bank raised its holdings in Ironwood Pharmaceuticals by 2.2% in the fourth quarter. Swiss National Bank now owns 282,700 shares of the biotechnology company’s stock worth $1,252,000 after buying an additional 6,000 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.